Comparative efficacy of bisphosphonates in metastatic breast and prostate cancer and multiple myeloma: A mixed-treatment meta-analysis

Clinical Cancer Research

Volumn 19, Issue 24, 2013, Pages 6863-6872

  Palmieri, Carlo ^a,b,c   Fullarton, John R ^d   Brown, Janet ^e  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^c CLATTERBRIDGE CENTRE FOR ONCOLOGY   (United Kingdom)

^d Fullarton Consultancy   (United Kingdom)

^e UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; PLACEBO; ZOLEDRONIC ACID;

ARTICLE; BONE DISEASE; BONE METASTASIS; BONE PAIN; BRACE; BREAST CANCER; DRUG EFFICACY; HUMAN; HYPERCALCEMIA; META ANALYSIS; MULTIPLE MYELOMA; ORTHOPEDIC SURGERY; PATHOLOGIC FRACTURE; PRIORITY JOURNAL; PROSTATE CANCER; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SKELETAL RELATED EVENT; SPINAL CORD COMPRESSION;

BREAST NEOPLASMS; CLODRONIC ACID; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; MALE; MULTIPLE MYELOMA; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS;

EID: 84890708496     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-2275     Document Type: Article

References (53)

1. Coleman RE. Skeletal complications of malignancy. Cancer 1997;80 Suppl 8:1588-94. (Pubitemid 27444031)
2. Coleman RE. Metastatic bone disease: clinical features, pathophys-iology and treatment strategies. Cancer Treat Rev 2001;27:165-76. (Pubitemid 32452017)
3. Loftus LS, Edwards-Bennett S, Sokol GH. Systemic therapy for bone metastases. Cancer Control 2012;19:145-53.
4. Cameron D. Proven efficacy of zoledronic acid in the treatment of bone metastases in patients with breast cancer and other malignancies. Breast 2003;12:S22-9. (Pubitemid 40023560)
5. Saad F, Lipton A, Cook R, Chen YM, Smith M, Coleman R. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 2007;110:1860-7. (Pubitemid 47557312)
6. Pockett RD, Castellano D, McEwan P, Oglesby A, Barber BL, Chung K. The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain. Eur J Cancer Care 2010;19:755-60.
7. Groot MT, Boeken Kruger CG, Pelger RCM, Uyl-de Groot CA. Costs of prostate cancer, metastatic to the bone, in the Netherlands. Eur Urol 2003;43:226-32. (Pubitemid 36314233)
8. Aapro M, Abrahamsson PA, Body JJ, Coleman RE, Colomer R, Costa L, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 2008; 19:420-32.
9. Terpos E, Sezer O, Croucher PI, García-Sanz R, Boccadoro M, San Miguel J, et al. The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Ann Oncol 2009;20:1303-17.
10. Coleman RE. Bisphosphonates in breast cancer. Ann Oncol 2005;16: 687-95. (Pubitemid 40767087)
11. Caraglia M, Marra M, Naviglio S, Botti G, Addeo R, Abbruzzese A. Zoledronic acid: an unending tale for an antiresorptive agent. Expert Opin Pharmacother 2010;11:141-54.
12. Wong MH, Stockler MR, Pavlakis N. Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev 2012;2: CD003474.
13. Mhaskar R, Redzepovic J, Wheatley K, Clark OA, Miladinovic B, Glasmacher A, et al. Bisphosphonates in multiple myeloma: a network meta-analysis. Cochrane Database Syst Rev 2012;5:CD003188.
14. Yuen KK, Shelley M, Sze WM, Wilt T, Manson MD. Bisphosphonates for advanced prostate cancer. Cochrane Database Syst Rev 2006;4: CD006250.
15. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003;98:1735-44. (Pubitemid 37238631)
16. Barrett-Lee PJ, Casbard A, Abraham J, Grieve R, Wheatley D, Simmons P, et al. Zoledronate versus ibandronate comparative evaluation (ZICE) trial-first results of a UK NCRI 1, 404 patient phase III trial comparing oral ibandronate versus intravenous zoledronate in the treatment of breast cancer patients with bone metastases [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium; 2012 Dec 4-8; San Antonio, TX.
17. Morgan GJ, Child JA, Gregory WM, Szubert AJ, Cocks K, Bell SE, et al. Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial. Lancet Oncol 2011;12:743-52.
18. Body JJ, Lichinitser M, Tjulandin S, Garnero P, Bergstro€m B. Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metas-tases. Ann Oncol 2007;18:1165-71. (Pubitemid 47244361)
19. Francini F, Pascucci A, Bargagli G, Francini E, Conca R, Miano ST, et al. Effects of intravenous zoledronic acid and oral ibandronate on early changes in markers of bone turnover in patients with bone metastases from non-small cell lung cancer. Int J Clin Oncol 2011;16:264-9.
20. Green JR, M€uller K, Jaeggi KA. Preclinical pharmacology of CGP 42446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 1994;9:745-51. (Pubitemid 24130477)
21. National Institute for Health and Clinical Excellence Publication. CG81 Advanced breast cancer: NICE guideline. February 2009.
22. Sutton A, Ades AE, Cooper N, Abrams K. Use of indirect and mixed treatment comparisons for technology assessment. Pharmacoeco-nomics 2008;26:753-67.
23. Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 2005;331:897-900. (Pubitemid 41502718)
24. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. June 2008.
25. Singh JA, Wells GA, Christensen R, Tanjong Ghohomu E, Maxwell L, Macdonald JK, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011; CD008794.
26. Filippini G, Del Giovane C, Vacchi L, D'Amico R, Di Pietrantonj C, Beecher D, et al. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis. Cochrane Database Syst Rev 2013;CD008933.
27. Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010;28:5132-9.
28. Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011;377:813-22.
29. Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011;29:1125-32.
30. Amgen Limited. Xgeva summary of product characteristics. Available at: https://www.medicines.org.uk/EMC/medicine/24755/SPC/XGEVA/[Accessed November 2013].
31. Lunn DJ, Thomas A, Best N, Spiegelhalter D. WinBUGS-a Bayesian modelling framework: concepts, structure and extensibility. Stat Com-put 2000;26:325-37.
32. MRC Biostatistics Unit, Cambridge, UK. The BUGS project. [cited 2012 Dec]. Available from: http://www.mrc-bsu.cam.ac.uk/bugs/.
33. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004;96:879-82. (Pubitemid 38807610)
34. Aviles A, Nambo MJ, Neri N, Castaneda C, Cleto S, Huerta-Guzman J. Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma. Med Oncol 2007;24:227-30. (Pubitemid 350135975)
35. Musto P, Petrucci MT, Bringhen S, Guglielmelli T, Caravita T, Bon-garzoni V, et al. A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma. Cancer 2008;113:1588-95.
36. Kohno N, Aogi K, Minami H, Nakamura S, Asaga T, Lino Y, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 2005;23:3314-21.
37. Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD, Mellars K, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 2000;88:1082-90. (Pubitemid 30127670)
38. Small EJ, Smith MR, Seaman JJ, Ptrone S, Kowalski MO. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol 2003;21:4277-84. (Pubitemid 46621802)
39. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol 1998;16:593-602. (Pubitemid 28135605)
40. Musto P, Falcone A, Sanpaolo G, Bodenizza C, Cascavilla N, Melillo L, et al. Pamidronate reduces skeletal events but does not improve progression-free survival in early-stage untreated myeloma: results of a randomized trial. Leuk Lymphoma 2003;44:1545-8. (Pubitemid 36833970)
41. Paterson AH, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley S. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993;11:59-65. (Pubitemid 23059975)
42. Dearnaley DP, Sydes MR, Mason MD, Stott M, Powell CS, Robinson AC, et al. A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). J Natl Cancer Inst 2003;95:1300-11. (Pubitemid 37160863)
43. Lahtinen R, Laakso M, Palva I, Virkkunen P, Elomaa I. Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group. Lancet 1992;340:1049-52.
44. Body JJ, Diel IJ, Lichinitser MR, Kreuser ED, Dornoff W, Gorbunova VA, et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 2003;14:1399-405. (Pubitemid 37185286)
45. Menssen HD, Sakalova A, Fontana A, Hermann Z, Boewer C, Facon T, et al. Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers n patients with advanced multiple myeloma. J Clin Oncol 2002; 20:2353-9. (Pubitemid 34441663)
46. Body JJ, Diel IJ, Lichinitzer M, Lazarev A, Pecherstorfer M, Bell R, et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer 2004;90: 1133-7. (Pubitemid 38496803)
47. McCloskey EV, MacLennan IC, Drayson MT, Chapman C, Dunn J, Kanis JA. A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults. Br J Haematol 1998;100:317-25. (Pubitemid 28131063)
48. McCloskey EV, Dunn JA, Kanis JA, MacLennan IC, Drayson MT. Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma. Br J Haematol 2001;113:1035-43. (Pubitemid 32634773)
49. Mangiapane S, Hoer A, Gothe H, Barghout V, Haeussler B. Higher persistency with i. v. bisphosphonates in patients with bone metastases. J Clin Oncol 24, 2006(suppl; abstr 18623).
50. Henk HJ, Teitelbaum A, Perez JR, Kaura S. Persistency with zoledronic acid is associated with clinical benefit in patients with multiple myeloma. Am J Hematol 2012;87:490-5.
51. Lipton A. Improving progression-free and overall survival in patients with cancer: a potential role for bisphosphonates. Expert Opin Phar-macother 2011;12:749-62.
52. Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 2012;48:3082-92.
53. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate cancer. J Natl Cancer Inst 2002;94:1458-68.